GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laboratorio Reig Jofre SA (XMAD:RJF) » Definitions » Gross Profit

Laboratorio Reig Jofre (XMAD:RJF) Gross Profit : €85.9 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Laboratorio Reig Jofre Gross Profit?

Laboratorio Reig Jofre's gross profit for the three months ended in Dec. 2023 was €41.7 Mil. Laboratorio Reig Jofre's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was €85.9 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Laboratorio Reig Jofre's gross profit for the three months ended in Dec. 2023 was €41.7 Mil. Laboratorio Reig Jofre's Revenue for the three months ended in Dec. 2023 was €78.8 Mil. Therefore, Laboratorio Reig Jofre's Gross Margin % for the quarter that ended in Dec. 2023 was 52.88%.

Laboratorio Reig Jofre had a gross margin of 52.88% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Laboratorio Reig Jofre was 65.20%. The lowest was 54.04%. And the median was 61.75%.

Warning Sign:

Laboratorio Reig Jofre SA gross margin has been in long-term decline. The average rate of decline per year is -2.8%.


Laboratorio Reig Jofre Gross Profit Historical Data

The historical data trend for Laboratorio Reig Jofre's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorio Reig Jofre Gross Profit Chart

Laboratorio Reig Jofre Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.10 140.40 144.98 157.34 179.01

Laboratorio Reig Jofre Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.19 41.66 - 44.20 41.67

Competitive Comparison of Laboratorio Reig Jofre's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorio Reig Jofre's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's Gross Profit distribution charts can be found below:

* The bar in red indicates where Laboratorio Reig Jofre's Gross Profit falls into.



Laboratorio Reig Jofre Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Laboratorio Reig Jofre's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=316.088 - 137.076
=179.0

Laboratorio Reig Jofre's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=78.806 - 37.132
=41.7

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €85.9 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Laboratorio Reig Jofre's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=41.7 / 78.806
=52.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Laboratorio Reig Jofre  (XMAD:RJF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Laboratorio Reig Jofre had a gross margin of 52.88% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Laboratorio Reig Jofre Gross Profit Related Terms

Thank you for viewing the detailed overview of Laboratorio Reig Jofre's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorio Reig Jofre (XMAD:RJF) Business Description

Traded in Other Exchanges
Address
Avenida de les Flors, Sant Joan Despi, Barcelona, ESP, 08970
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.